PFE

Pfizer Inc.

Fundamental data last updated:July 3, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - General

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

 


VALUATION

P/E

19.73

Market Cap ($M USD)

$148.01B

Forward P/E

10.80

PEG

0.13

PRICE TO SALES

2.34

PRICE TO BOOK

1.64

EV / EBITDA

12.44

5-Year Average P/E

Free Cash Flow Yield

6.41%

DCF Value

$39.96

Graham Number

$21.65

Price to FCF

15.61

EV to FCF

22.22

Earnings Yield

5.07%

FCF Yield

6.41%

DIVIDEND

Yield

6.62%

Annual Payout

$1.72

Payout Ratio

130.54%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.32

Next Year EPS Growth Estimate

$2.40

Next Year Revenue Growth Estimate

$5.38T

Return on Equity (ROE)

8.37%

FREE CASH FLOW

Operating Margin

23.45%

Debt-to-Equity

0.78

Piotroski F-Score

5

Altman Z-Score

2.08

Return on Invested Capital (ROIC)

8.57%

Current Ratio

1.25

Quick Ratio

0.94

Net Debt to EBITDA

3.70

Interest Coverage

5.53

Gross Profit margin

69.35%

FCF PER SHARE

$1.67

REVENUE PER SHARE

$11.13

Gainseekers Quantitative Analysis

Summary

Pfizer Inc. appears to be significantly undervalued based on its DCF Value of $38.71 compared to recent pricing, suggesting a potential mispricing by the market. The Forward P/E of 10.74 indicates a more attractive valuation relative to its current earnings, while the Earnings Yield of 5.10% provides a reasonable return expectation. However, the Altman Z-score of 2.07 raises concerns about financial stability, hinting at moderate distress risk. Overall, the stock’s valuation metrics suggest a compelling opportunity for value investors, though caution is warranted given the financial health indicators.

AI Exposure / Tech Reliance

Operating in the healthcare sector, Pfizer is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The company's focus on innovation and R&D could enhance its adaptability to technological shifts. This resilience is crucial in maintaining its competitive edge in a rapidly evolving industry.

The Bull Case

For value or GARP investors, Pfizer's appeal lies in its robust ROIC of 8.57% and a solid Free Cash Flow Yield of 6.44%, indicating efficient capital use and strong cash generation. The Piotroski F-Score of 5 suggests moderate financial health, while an Operating Margin of 23.45% underscores its pricing power. These metrics collectively paint a picture of a company with the potential for sustainable growth and profitability, making it an attractive buy for those seeking undervalued opportunities with solid fundamentals.

The Bear Case

Despite its strengths, Pfizer faces structural risks, particularly with a high Payout Ratio of 130.54%, which questions the sustainability of its dividend. The Price to Free Cash Flow ratio of 15.52 suggests the stock might be overvalued relative to its cash generation capabilities. Additionally, the stock's proximity to its 52-week high, with only an 11.33% distance, indicates potential technical overextension. These factors could deter cautious investors wary of overvaluation and cash flow constraints.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$27.00

Institutional Ownership %

1-Year Beta

0.31

Insider Buying % (6 Mo)

Distance to 52-Week High

10.70%

Distance to 52-Week Low

11.21%

EARNINGS SURPRISE %

3.88%

50-DAY SMA

$26.76

200-DAY SMA

$25.83

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.